Related Experiment Video
Updated: Nov 25, 2025

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
A Multifunctional LNA Oligonucleotide-Based Strategy Blocks AR Expression and Transactivation Activity in PCa Cells
Daniela Castanotto1, Xiaowei Zhang1, Jacqueline Rüger1
1Department of Medical Oncology, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA.
Abstract:
The androgen receptor (AR) plays a critical role in the development of prostate cancer (PCa) through the activation of androgen-induced cellular proliferation genes. Thus, blocking AR-mediated transcriptional activation is expected to inhibit the growth and spread of PCa. Using tailor-made splice-switching locked nucleic acid (LNA) oligonucleotides (SSOs), we successfully redirected splicing of the AR precursor (pre-)mRNA and destabilized the transcripts via the introduction of premature stop codons. Furthermore, the SSOs simultaneously favored production of the AR45 mRNA in lieu of the full-length AR. AR45 is an AR isoform that can attenuate the activity of both full-length and oncogenic forms of AR by binding to their common N-terminal domain (NTD), thereby blocking their transactivation potential. A large screen was subsequently used to identify individual SSOs that could best perform this dual function. The selected SSOs powerfully silence AR expression and modulate the expression of AR-responsive cellular genes. This bi-functional strategy that uses a single therapeutic molecule can be the basis for novel PCa treatments. It might also be customized to other types of therapies that require the silencing of one gene and the simultaneous expression of a different isoform.
Insights
New splice-switching oligonucleotides (SSOs) target the androgen receptor (AR) in prostate cancer (PCa). These SSOs block AR
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- The androgen receptor (AR) is crucial for prostate cancer (PCa) progression by activating androgen-induced genes.
- Inhibiting AR-mediated transcription is a key strategy to control PCa growth and metastasis.
Purpose of the Study:
- To develop novel therapeutic molecules targeting the androgen receptor (AR) for prostate cancer (PCa) treatment.
- To investigate the potential of splice-switching oligonucleotides (SSOs) to modulate AR splicing and function.
Main Methods:
- Utilized tailor-made splice-switching locked nucleic acid (LNA) oligonucleotides (SSOs) to alter AR precursor mRNA splicing.
- Introduced premature stop codons to destabilize AR transcripts and favored the production of the AR45 isoform.
- Screened SSOs for dual function: silencing full-length AR and promoting the inhibitory AR45 isoform.
Main Results:
- SSOs successfully redirected AR pre-mRNA splicing, leading to transcript destabilization and reduced full-length AR.
- Selected SSOs promoted the expression of AR45, an AR isoform that antagonizes AR activity.
- The developed SSOs effectively silenced AR expression and modulated AR-responsive genes.
Conclusions:
- A bi-functional SSO strategy offers a novel therapeutic approach for prostate cancer (PCa) by targeting AR.
- This approach simultaneously silences AR and promotes an inhibitory AR isoform (AR45).
- The strategy is potentially adaptable for other therapies requiring gene silencing and isoform modulation.
More Related Videos
Related Concept Videos
lncRNA - Long Non-coding RNAs
Targeted Cancer Therapies
There are several types of targeted therapies against...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

